# Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer

> **NCT03740191** · NA · TERMINATED · sponsor: **EBG MedAustron GmbH** · enrollment: 5 (actual)

## Conditions studied

- Low Risk Prostate Cancer
- Intermediate Risk Prostate Cancer

## Interventions

- **OTHER:** EPIC questionnaire
- **RADIATION:** kV x-ray images
- **RADIATION:** Conebeam CT

## Key facts

- **NCT ID:** NCT03740191
- **Lead sponsor:** EBG MedAustron GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-03
- **Primary completion:** 2025-03-14
- **Final completion:** 2025-03-14
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Recuitment target for patient enrollment was not met.
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740191, "Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03740191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*